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Abstract: 
Objectives:   
To develop a Glucocorticoid Toxicity Index (GTI) to assess glucocorticoid (GC)-related 
morbidity and the GC-sparing ability of other therapies.  
 
Methods:   
Nineteen experts on glucocorticoid use and outcome measures from 11 subspecialties 
participated.  Ten experts were from the United States; 9 from Canada, Europe, or Australia.  
Group consensus methods and multi-criteria decision analysis (MCDA) were utilized. 
  
A Composite GTI and Specific List comprise the overall GTI.  The Composite GTI reflects 
toxicity likely to change during a clinical trial.  The Composite GTI toxicities occur commonly, 
vary with GC exposure, and are weighted and scored. Relative weights for items in the 
Composite GTI were derived by group consensus and MCDA.  The Specific List is designed to 
capture GC toxicity not included in the Composite GTI.  The Composite GTI was evaluated by 
application to paper cases by the investigators and an external group of 17 subspecialists. 
 
Results:   
Thirty-one toxicity items were included in the Composite GTI and 23 in the Specific List. 
Composite GTI evaluation showed high inter-rater agreement (investigators kappa 0.88, external 
raters kappa 0.90). To assess the degree to which the Composite GTI corresponds to expert 
clinical judgment, participants ranked 15 cases by clinical judgment in order of highest to lowest 
GC toxicity.  Expert rankings were then compared to case ranking by the Composite GTI, 
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yielding excellent agreement (investigators weighted kappa 0.87, external raters weighted kappa 
0.77).  
 
Conclusions:   
We describe the development and initial evaluation of a comprehensive instrument for the 
assessment of glucocorticoid toxicity.  
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INTRODUCTION 
Glucocorticoids (GCs) have been a cornerstone of treatment for many diseases since their 
introduction more than sixty-five years ago.  GC use is associated with considerable treatment 
morbidity.1,2 Although the use of these medications is generally reviled by patients and 
physicians alike, data on the true incidence of GC-associated adverse events remain scarce 
because until now GC toxicity has simply been a fact of life for patients with immune-mediated 
diseases.3  The development of novel immunomodulatory agents offers the potential to reduce 
GC use and to diminish their adverse effects.4,5  In order to assess the true benefit of new 
medications with regard to their steroid-sparing properties, investigators must be able to assess 
their ability to prevent or reverse GC-related adverse events.  Unfortunately, no reliable 
instrument designed to measure GC-related toxicity both broadly and accurately has been 
developed.  
 
Measuring GC-related toxicity poses significant challenges.1,6 Previous studies examining GC-
related toxicity have utilized different combinations of adverse events with varied event 
definitions.7,8,9  We aimed to develop a GC Toxicity Index (GTI) useful across medical 
disciplines to assess the impact of GC-associated morbidity.  
 
METHODS 
Participants and procedures 
Twenty-two experts in glucocorticoid use and outcome measures were invited and 19 agreed to 
serve on the Scientific Committee (SC).  Experts represented multiple specialties (rheumatology 
[including osteoporosis], pediatric rheumatology, pulmonology, nephrology, neurology, 
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ophthalmology, dermatology, infectious disease, and psychiatry) and had extensive experience in 
the clinical use and pharmacology of GCs.  Ten investigators were from the United States, nine 
from Canada, Europe, or Australia.   
 
The development process, which included ten milestones (Figure 1), was conducted over ten 
one-hour conference calls, work between the calls, and one day-long, face-to-face meeting.   
 
Instrument characteristics and item inclusion criteria 
The SC agreed that the optimal use of the GTI would be in prospective, randomized, controlled 
clinical trials utilizing GCs, regardless of whether GC therapy is prescribed according to protocol 
or investigators’ best medical judgement.  Randomization and blinding serve the critical 
purposes of controlling for the background rate of adverse events10 and prior GC treatment, and 
also limit the need for attribution.  
 
The SC determined that the GTI would have two components: the Composite GTI and a Specific 
List.  The Composite GTI serves as the primary instrument and is intended to capture common 
toxicities that are sensitive to differing cumulative GC doses over the period of a typical clinical 
trial (6 months to 3 years).  It is weighted and measures both worsening and improvement.  The 
complementary Specific List captures important GC-related adverse events not included in the 
Composite GTI.  The SC agreed to not weigh Specific List toxicities due to the possible skewing 
that rare but serious events would introduce into the weighting scheme.   
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Item selection for the Composite GTI was based on the following principles: 1) likelihood of 
occurrence >5% in patients exposed to GCs; 2) item independence; 3) item equivalence (several 
GC toxicities could be included within a single item, provided they were within the same clinical 
domain and were equivalent in their degree of toxicity); 4) toxicity is more likely to be due to the 
effect of GC therapy than the disease itself; 5) toxicity is unlikely to be the result of GC therapy 
prior to trial entry (e.g., osteoporotic fracture); 6) measurement does not typically require 
invasive procedures or imaging.   
 
Toxicities that did not meet these criteria but were deemed important and were not confounded 
by underlying disease or co-morbidities were included in the Specific List.  Candidate toxicities 
were generated based on literature review (Appendix I) and selected for inclusion by nominal 
group technique.  Definitions for each item, developed by experts from the relevant clinical area, 
were revised by consensus.  Items were grouped by clinical domains in order of increasing 
toxicity such that only one item within each domain could be assigned to a given patient.  The 
draft GTI was reviewed by the SC for clarity, format, visual design, organization, and 
navigability.  Relative weights were then derived at the face-to-face meeting using multi-criteria 
decision analysis (MCDA) via the 1000Minds software platform (Dunedin, New Zealand) 
(Appendix II).11,12 
 
Instrument scoring 
The SC agreed that the Composite GTI should measure change in GC toxicity rather than 
absolute GC toxicity in order to account for the effects of prior GC therapy and background rate 
of adverse events.  Therefore, evaluation at two time points is required for scoring.  All domains 
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have the potential for improvement (e.g., myopathy can improve from “mild” to “none”, even 
though a specific improvement item is not included in the Composite GTI).  When a Specific 
List item occurs (e.g., death from infection), the most severe corresponding item in the 
Composite GTI (i.e., Grade 3 infection) is also scored.  The Composite GTI should be scored at 
3-month intervals throughout the study, using entry assessment as the baseline.  Because the 
bone domain should generally not be scored more often than every 12 months, it should be 
excluded for trials shorter than 1 year in duration. The score should be reported as both a total 
score and domain-specific scores, to account for scenarios when improvements in certain 
domains compensate for worsening in others. 
 
Evaluation process 
The performance of the Composite GTI was evaluated by both participating experts and an 
external, multi-specialty group of 17 testers (Supplementary Table 1) using paper cases.  Each 
expert submitted four patient cases describing GC toxicity.  Fifteen cases were chosen to 
represent the full range of GC toxicity.  Both the experts and external testers then completed an 
on-line exercise composed of two tasks: 1) rank cases in order of greatest to least GC-toxicity 
(experts’ rankings were then compared to the ranking assigned by the weighted Composite GTI); 
and, 2) assign Composite GTI items to each case.   
 
Statistical Analysis 
Interrater reliability among raters and agreement between the experts’ and external testers’ 
rankings and those of the Composite GTI were assessed using the Kappa statistic.  The overall 
interrater reliability of the ranking agreements was then calculated by averaging pairwise Kappa 
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values.  All statistical analyses were performed on SAS Version 9.3 (SAS Institute, Cary, NC, 
USA). 
 
RESULTS   
Nine domains and 31 items were included in the Composite GTI (Table 1).  Eleven domains and 
23 items were included in the Specific List (Table 1)(See definitions, Appendices III and IV).  
Items reflect severity and account for impact of medications (e.g., blood pressure can be stable 
due to an increase in anti-hypertensive regimen).  Toxicities such as atherosclerosis, myocardial 
infarction, and stroke were not included in the GTI because the SC agreed that all are 
confounded by co-morbid conditions (e.g., smoking) or disease effects (e.g., systemic lupus 
erythematosus).13  Except for bone mineral density, included because of its importance in GC-
related toxicity,14  items requiring imaging were excluded from the Composite GTI.   
 
Fifteen experts participated in the weighting exercise at the face-to-face meeting.  Seventeen of 
19 experts and 17 independent raters completed this evaluation phase.  The interrater reliability 
exercise revealed a high degree of agreement, with a kappa of 0.88 (P<0.01) for participating 
experts and kappa of 0.90 (P<0.01) for independent raters.  The initial validity exercise revealed 
that both expert and independent rater case rankings had excellent agreement with rankings by 
the Composite GTI with a weighted kappa of 0.87 (P<0.01) and 0.77 (P<0.01), respectively.   
 
DISCUSSION 
A useful measurement of the steroid-sparing ability of new treatment agents requires a reliable 
outcomes-based instrument of GC-related toxicity.15,16  We describe a multi-specialty effort to 
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develop the GTI, a comprehensive measure of change in GC-toxicity over time.  The initial 
evaluation of the Composite GTI by participating experts and a multi-specialty group of external 
testers demonstrated excellent reliability and validity.   
 
The development of two complementary assessment instruments within the GTI – the Composite 
GTI and the Specific List – was crucial in addressing several challenges in measuring GC 
toxicity.  The creation of the Specific List permits documentation of certain important and often 
severe toxicities, leaving the Composite GTI as a relatively concise and easy to administer tool 
intended to detect differences between patients receiving divergent GC amounts.  The inclusion 
of rare toxicities and those that may reflect prior GC use in the Specific List allowed us to 
simplify the usability, limit weight skewing, and minimize the effect of pre-trial GC therapy on 
the Composite GTI.   
 
An important strength of the Composite GTI is the assignment of relative weights to each 
toxicity item in a systematic manner using MCDA.11  The MCDA approach greatly enhances the 
feasibility of this complex task in a way that group consensus methods struggle to approach. 
Further, the MCDA approach allows us to perform modifications of the Composite GTI as new 
data become available, including the addition and weighting of new items, without disrupting the 
validity of the method. 
 
The next phase in GTI development includes the development of a web-based interface, 
prospective use in clinical trials, and input from patient support groups.  Our initial evaluation 
exercise of the Composite GTI, including testing by an external group of glucocorticoid experts, 
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implies excellent performance characteristics.  The development of a web-based interface should 
further increase the instrument’s reliability.  For the GTI to be truly valid, it must be assessed in 
clinical trials and compared to doses of GCs administered, quality-of-life measures, and damage 
indices that include GC toxicity.17,18  
 
In conclusion, we describe the development and initial evaluation of the GTI, a comprehensive 
GC toxicity assessment instrument.  The GTI can be used across disciplines to assess the clinical 
value of steroid-sparing therapies, as well as to measure the impact of GC toxicity.  Given the 
widespread use of GCs and the accelerating pace of immunological drug discovery, this 
instrument represents a considerable advance in our ability to assess the utility of new 
pharmacologic agents. 
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Figure Titles 
Figure 1 – GTI development milestones 
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Composite GTI 
Item 
Weight Specific List 
Body mass index     
  Improvement in BMI -8 Major increase in BMI 
  No change in BMI 0   
  Moderate increase in BMI 21   
  Major increase in BMI 36   
Glucose tolerance     
  Improvement in glucose tolerance -8 Diabetic retinopathy 
  No change in glucose tolerance 0 Diabetic nephropathy 
  Worsening of glucose tolerance 32 Diabetic neuropathy 
  
Worsening of glucose tolerance despite 
treatment 44   
Blood pressure     
  Improvement in blood pressure -10 Hypertensive emergency 
  No change in blood pressure 0 
Posterior reversible encephalopathy 
syndrome 
  Worsening hypertension 19   
  Worsening hypertension despite treatment 44   
Lipids     
  Improvement in lipids -9   
  No change in lipids 0   
  Worsening hyperlipidemia 10   
  Worsening hyperlipidemia despite treatment 30   
Bone density     
  Improvement in bone density -1 Major decrease in bone density 
  No change in bone density 0 Insufficiency fracture  
  Decrease in bone density 29 
Steroid myopathy     
  No steroid myopathy 0 Severe steroid myopathy 
  Mild steroid myopathy 9   
  Moderate steroid myopathy or greater 63   
Skin toxicity     
  No skin toxicity 0 Severe skin toxicity 
  Mild skin toxicity 8   
  Moderate skin toxicity or greater 26   
Neuropsychiatric toxicity     
  No neuropsychiatric symptoms 0 Psychosis 
  Mild neuropsychiatric symptoms 11 GG-induced violence 
  Moderate neuropsychiatric symptoms or greater 74 Other severe neuropsychiatric symptoms 
Infection     
  No significant infection 0 Grade 4 infection 
  Oral/vaginal candidiasis or uncomplicated zoster 19 Grade 5 infection 
  Grade 3 infection or greater 93   
Endocrine   Adrenal insufficiency  
Gastrointestinal   Perforation  
    Peptic ulcer disease 
Musculoskeletal   Avascular necrosis  
    Tendon rupture 
Ocular   Central serous retinopathy  
    Intraocular pressure elevation 
    Posterior subcapsular cataract 
Total -36 to 439   
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Appendix II – Multi-Criteria Decision Analysis Methods 
 
Multi-criteria decision analysis can be utilized to assign weights to items by ranking all 
possible combinations in order of severity of toxicity.  1000Minds software facilitates the 
process by determining the point values of multi-attribute value models and has been 
used in studies in healthcare, corporate management, agriculture, and environmental 
management.1  1000Minds employs the “Potentially All Pairwise Rankings of all possible 
Alternatives” (PAPRIKA) method.2  PAPRIKA is based on the principle that an overall 
ranking of items in a model can be achieved if all possible pairwise combinations of the 
included items can be ranked.  Ranking in a pairwise manner carries less cognitive 
burden then ranking multiple criteria simultaneously.  Because the total number of 
pairwise rankings can number in the thousands, 1000Minds limits the number of pairwise 
rankings using the property of transitivity (if A > B and B > C, then A > C).  Any 
pairwise decision in which one option clearly has a higher weight (in this case, greater 
toxicity) based upon the outcomes of previous comparisons is not presented for 
consideration, thereby creating an efficiency of comparisons and permitting hundreds of 
comparisons within a few hours. 
 
Participants were asked to assess the relative weight (toxicity) of items by selecting the 
higher toxicity from a paired patient scenario differing in two toxicity items.  Figure 1 
shows examples of the types of comparisons the Scientific Committee was made asked to 
make in deciding which combinations of clinical GC complications of GC use constituted 
the higher degree ofgreater GC toxicity.  Using Turning Point voting technology 
(Youngstown, Ohio), experts anonymously chose the scenario with higher GC toxicity.  
The results of each vote were immediately presented to the full Scientific Committee and 
reasons for disagreement, if present, were discussed.  If there was significant 
disagreement, the group re-voted after discussion of disagreements. This step was 
repeated if necessary.  Consensus was achieved when all participants reached agreement 
or could accept the majority decision.   
 
Based on the number of domains and toxicity items, there were 62,208 possible paired 
patient scenarios differing in two toxicity items.  The participants completed 103 
scenarios, reaching agreement on all combinations.  The remaining 62,105 scenarios were 
then implicitly resolved using the transitivity principle within the 1000Minds software.   
Through iterative discrete pairwise choices, 1000Minds assigned relative weights to the 
items. 
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Figure 1 
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 1 
Appendix III - Composite Glucocorticoid Toxicity Index 
 
 
1. Body Mass Index (BMI) (compared to baseline) 
a. Improvement in the direction of the normal range by more than 2 BMI units [normal range = 18.5-24.9 kg/m2]  
b. No significant change (BMI remains within +/- 2 BMI units compared with baseline) 
OR BMI remains within the normal range 
c. Moderate increase in BMI (increase by more than 2 but less that 5 BMI units, to above the upper limit of normal BMI [24.9 kg/m2]) 
d. Major increase in BMI (increase by at least 5 but less than 8 BMI units above normal BMI [24.9 kg/m2]) 
 
 
2. Glucose Tolerance (compared to baseline) 
a. Improvement in glucose tolerance:  
• HbA1c declined >10% from baseline without medication increase 
OR 
• Decrease in diabetic medication without an increase in HbA1c of >10% or HbA1c < 5.7% 
b. No significant change in glucose tolerance: 
• HbA1c within 10% of baseline or HbA1c < 5.7% AND no change in medication  
OR  
• HbA1c increased to > 10% of baseline with a decrease in medication  
OR  
• HbA1c decreased by > 10% of baseline with an increase in medication 
c. Worsening of glucose tolerance or medication status:  
• HbA1c > 5.7% and increased to >10% of baseline without a change in medication  
OR  
• Increase in diabetic medication with < 10% increase in HbA1c 
d. Worsening of glucose tolerance despite increased treatment: 
• HbA1c > 5.7% AND increased to >10% of baseline AND an increase in diabetic medication 
 
 
3. Blood Pressure (BP) (compared to baseline) 
a. Improvement in BP:  
• Decrease in BP of >10% of baseline without medication increase, unless baseline systolic BP ≤ 120 and diastolic BP ≤ 85 
OR 
• Decrease in medication without an increase in BP of >10%, unless baseline systolic BP ≤ 120 and diastolic BP ≤ 85 
b. No significant change in BP: 
• BP within 10% of baseline or systolic BP ≤ 120 and diastolic BP ≤ 85 AND no change in medication  
                             OR  
• Increase in either systolic or diastolic BP >10% with a decrease in medication  
                             OR  
• Improvement in systolic or diastolic BP of > 10% with an increase in medication 
c. Worsening of hypertension:  
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 2 
• Increase in BP of >10% such that the systolic BP exceeds 120 mmHg or the diastolic BP exceeds 85 mmHg without a change in medication  
                             OR  
• An increase in anti-hypertensive medication accompanied by stability or no significant change in both the systolic and diastolic BP 
d. Worsening of hypertension despite treatment: 
• Increase in BP of >10% such that the systolic BP exceeds 120 mmHg or the diastolic BP exceeds 85 mmHg AND an increase in 
medication 
 
 
4. Lipid metabolism (low-density lipoprotein [LDL] compared to baseline) 
a. Improvement in lipids:  
• Decrease in LDL concentration >10% of baseline toward the target range without medication increase  
OR 
• Decrease in medication without an increase in LDL of >10% or LDL remains within target range 
b. No significant change in LDL: 
• LDL within 10% of baseline or within the target range for patient AND no change in medication  
                                    OR  
• Increase in LDL > 10% with a decrease in medication 
                                    OR  
• Improvement in LDL of > 10% with an increase in medication 
c. Worsening of LDL or medication status:  
• Increase in LDL of >10% to above target range without a change in medication 
                                    OR  
• Increase in medication with <10% change in LDL 
d. Worsening of LDL despite treatment: 
• Increase in LDL of >10% AND an increase in medication 
 
 
5. Bone Mineral Density (compared to baseline) 
a. Improvement – increase in BMD by >3% 
b. No significant change (BMD between -3% and +3% 
c. Deterioration - decrease in BMD (BMD decrease by ->3%) 
% refers to total BMD in gms/cm2 
 
6. Glucocorticoid-induced myopathy 
a. No steroid myopathy 
b. Mild steroid myopathy (weakness WITHOUT functional limitation) 
c. Moderate steroid myopathy (weakness WITH functional limitation) 
See Steroid Myopathy definitions, below 
 
7. Skin  
a. No skin toxicity 
b. Mild skin toxicity 
c. Moderate skin toxicity 
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 3 
See Skin definitions, below 
 
8. Neuropsychiatric toxicity  
a. No neuropsychiatric symptoms 
b. Mild neuropsychiatric symptoms 
c. Moderate neuropsychiatric symptoms 
See Neuropsychiatry definitions, below 
 
9. Infection (since last assessment)  
a. No significant infection 
b. Specific infections < Grade 3 (oral or vaginal candidiasis, uncomplicated zoster) 
c. Grade 3 or complicated herpes zoster 
See Infection definitions, below 
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 4 
Glucocorticoid-induced Myopathy Definitions 
Glucocorticoid-induced myopathy is defined as mild symmetrical weakness of the proximal muscles and/or neck flexors associated 
with steroid therapy, and NOT due to any other apparent cause. Muscle enzymes are typically within normal limits. 
Mild and moderate severity of myopathy are defined by a muscle strength of 4 on the standard Medical Research Council rating scale.   
A 4 means weaker than normal but greater than antigravity strength against resistance. 
“Mild” is mild weakness (Grade 4) that does NOT functionally limit the patient.  
”Moderate” is mild weakness (Grade 4) that does impose functional limitations on the patient enough to interfere with normal daily 
activities. 
Note that a person may have muscle weakness consistent with glucocorticoid-induced myopathy that detectable on physical 
examination but might not be aware of it or have any corresponding functional limitation - this would be classified as mild. 
Severe glucocorticoid-induced myopathy (defined as weakness of Grade 3 or less, which means no more than antigravity strength and 
unable to overcome any resistance or any degree weaker) is included in the Specific List. People who are severely weak may have 
difficulty rising from a chair without assistance or other major functional limitations but the formal categorization for severe should be 
based the degree of weakness on strength testing. 
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 5 
Severity of Glucocorticoid Toxicity in the Skin 
 
Manifestations to be considered: 
• Acneiform rash 
• Easy Bruising 
• Hirsutism 
• Atrophy/striae 
• Erosions/tears/ulcerations 
 
Skin 6b. Mild Skin 6c. Moderate Severe (Specific Domain) 
Acneiform rash (Grades 1-2) Acneiform rash (Grade 3) Acneiform rash (Grade 4) 
Easy bruising (Grade 1) Easy bruising (Grade 2)   
Hirsutism (Grade 1) Hirsutism (Grade 2)  
Atrophy/Striae (Grade 1) Atrophy/Striae (Grade 2) Atrophy/Striae (Grade 3) 
Erosions/Tears/Ulcerations (Grade 1) Erosions/Tears/Ulcerations (Grade 2) Erosions/Tears/Ulcerations (Grade 3) 
 
Skin Definitions (from National Cancer Institute Common Terminology Criteria for Adverse Events): 
 
Acneiform rash 
- Grade 1 - Papules and/or pustules covering <10% BSA, which may or may not be associated with symptoms of pruritus or tenderness 
- Grade 2 – Papules and/or pustules covering 10 - 30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; OR associated 
with psychosocial impact; OR limiting instrumental ADL 
- Grade 3 - Papules and/or pustules covering >30% BSA, which may or may not be associated with symptoms of pruritus or tenderness; OR limiting self 
care ADL; OR associated with local superinfection with oral antibiotics indicated 
- Grade 4 - Papules and/or pustules covering any % BSA, which may or may not be associated with symptoms of pruritus or tenderness and are associated 
with extensive superinfection with IV antibiotics indicated; OR life- threatening consequences 
Easy bruising 
- Grade 1 – Localized or in a dependent area 
- Grade 2 - Generalized 
 
Hirsutism  - In women, increase in length, thickness or density of hair in a male distribution 
- Grade 1 - Hirsutism that the patient is able to camouflage by periodic shaving, bleaching, or removal of hair 
- Grade 2 - Hirsutism that requires daily shaving or consistent destructive means of hair removal to camouflage; OR associated with psychosocial impact 
Atrophy / Striae 
- Grade 1 - Covering <10% BSA; OR associated with telangiectasias or changes in skin color 
- Grade 2 – Covering 10 - 30% BSA; OR associated with striae or adnexal structure loss 
- Grade 3 - Covering >30% BSA; OR associated with ulceration 
 
Erosions / Tears / Ulcerations 
- Grade 1 – Combined area of ulcers <1 cm; OR nonblanchable erythema of intact skin associated with warmth or erythema 
- Grade 2 – Combined area of ulcers 1 - 2 cm; OR partial thickness skin loss involving skin or subcutaneous fat 
- Grade 3 – Combined area of ulcers >2 cm; OR full-thickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend down to 
fascia 
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 6 
Severity of Neuropsychiatric Glucocorticoid Toxicity 
Manifestations to be considered: 
• Insomnia 
• Mania  
• Cognitive Impairment  
• Depression  
7b. Mild  7c. Moderate  Severe (Specific Domain) 
Insomnia – (Grade 1) Insomnia – (Grade 2)  
Mania (Grade 1) Mania (Grade 2) Mania (Grade 3) 
Cognitive impairment (Grade 1) Cognitive impairment (Grade 2) Cognitive impairment (Grade 3) 
Depression (Grade 1) Depression (Grade 2) Depression (Grade 3) 
 
Definitions of severity within the Neuropsychiatric Domain 
Insomnia - Dissatisfaction with sleep quality and difficulty initiating or maintaining sleep or early morning awakening 
- Grade 1: not associated with functional impairment  
- Grade 2:  associated with functional impairment  
Mania   
- Grade 1: Slightly or occasionally elevated or irritable mood and 0-1 mild or occasional additional symptoms of inflated self-esteem, decreased need for sleep, increased 
talkativeness, feeling that thoughts are faster than usual, distractibility, increased activity or agitation, and impulsive actions.  
- Grade 2: Frequent or moderately elevated or irritable mood and 2-3 mild additional symptoms of inflated self-esteem, decreased need for sleep, increased talkativeness, 
feeling that thoughts are faster than usual, distractibility, increased activity or agitation, and impulsive actions. 
- Grade 3: Severe or constantly elevated or irritable mood and 4 or more additional symptoms of inflated self-esteem, decreased need for sleep, increased talkativeness, 
feeling that thoughts are faster than usual, distractibility, increased activity or agitation, and impulsive actions.  
 
Cognitive impairment 
- Grade 1: Minor cognitive complaints, no objective findings on mental status examination (i.e., not apparent to the examiner) that were not present before initiating steroids 
- Grade 2: New moderate cognitive deficits that were not present before initiating steroids 
- Grade 3: Frank delirium  
 
Depression  
- Grade 1: Feeling slightly down or depressed and 0-2 mild or occasional addition symptoms of loss of interest, low energy, guilt, poor concentration, insomnia, restlessness, 
or change in appetite.  
- Grade 2: Frequent or moderate feelings of being down or depression and/or 3-4 symptoms of loss of interest, low energy, guilt, poor concentration, insomnia, restlessness, 
or change in appetite. 
- Grade 3: Severe constant feeling of being down or depression and/or 5 or more symptoms of loss of interest, low energy, guilt, poor concentration, insomnia, restlessness, 
or change in appetite and/or suicidal thoughts.  
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 7 
Infection Definitions 
No significant infection = No specific infections or serious infections, grade 3 or greater 
Specific Infections – Oral or vaginal candidiasis or zoster infections without post-herpetic neuralgia or eye involvement  
Grade 3 – Intravenous antibiotic, antifungal, or antiviral intervention or hospitalization indicated OR radiologic or operative intervention 
indicated OR herpes zoster complicated by post-herpetic neuralgia or eye involvement   
Grade 4 or 5 - Life-threatening consequences; urgent intervention indicated OR death from infection (included in the Specific List) 
  
References 
Medical Research Council of the United Kingdom. Guide to Examination of the Peripheral Nervous System: Memorandum No 45. Palo Alto, Calif: Pedragon House; 1978. 
National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009 NIH publication # 09-7473. 
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Appendix IV - Specific List 
 
 At 
Baseline 
or Before 
New Since 
Baseline 
Body Mass Index 
- An absolute increase in BMI of more than 8 units (and >24.9 kg/m2) 
 
  
Blood Pressure 
- Hypertensive emergency (see definition, below) 
- PRES (Posterior reversible encephalopathy syndrome) (see definition, below) 
 
  
Endocrine 
- Symptomatic adrenal insufficiency  
 
  
Bone Health 
- Osteonecrosis of one joint 
- Osteonecrosis of more than one joint 
- Bone mineral density decrease > 6% 
- Insufficiency fracture 
- Insufficiency fracture in more than one bone 
 
  
Muscle & Tendon 
- Severe glucocorticoid myopathy (see definition)   
- Tendon rupture 
- More than one tendon rupture 
 
  
Eye  
- Central serous retinopathy 
- New-onset or worsened elevation of intra-ocular pressure requiring treatment or change in treatment 
- Posterior subcapsular cataracts (or history of same) 
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Infection 
- Grade 4 infection (see definition, below) 
- Grade 5 infection (death from infection) 
 
  
Glucose Tolerance  
- Diabetic nephropathy  
- Diabetic neuropathy    
- Diabetic retinopathy  
 
  
Gastrointestinal Tract 
- Gastrointestinal perforation (occurring in the absence of regular nonsteroidal anti-inflammatory drug use) 
- Peptic ulcer disease confirmed by endoscopy (excluding H. pylori) 
 
  
Skin 
- Severe skin toxicity (see definition, below) 
 
  
Neuropsychiatric 
- Psychosis, defined as hallucinations, delusions, or disorganized thought processes (occurring in the absence 
of mania, delirium, or depression)  
- Glucocorticoid-induced violence toward self or others 
 
  
Other glucocorticoid toxicities 
 
Please specify: ____________________________________________________ 
                            
                           ____________________________________________________ 
 
                           ____________________________________________________ 
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DEFINITIONS: 
 
Hypertensive emergency: The blood pressure has reached levels that are damaging organs. Hypertensive emergencies generally occur at blood 
pressure levels exceeding 180 mmHg systolic OR 120 mmHg diastolic, but can occur at even lower levels in patients whose blood pressure have 
not been elevated before.  Complications can include: stroke, loss of consciousness, memory loss, myocardial infarction, hypertensive retinopathy 
or nephropathy, aortic dissection, angina, pulmonary edema. 
 
Posterior reversible leukoencephalopathy syndrome (PRES): A clinical radiological entity. Clinical features may include headaches, altered 
mental status, seizures, and visual loss, depending on the affected neuroanatomy. Characteristic Magnetic Resonance Imaging (MRI) findings 
include vasogenic edema involving the white matter that predominantly affects the posterior occipital and parietal lobes of the brain, although 
other brain regions may also be affected. Confirmation by MRI is required as is exclusion of other potential causes (including hypertensive 
emergency).     
 
Severe glucocorticoid myopathy: Grade 3 or worse myopathic weakness or respiratory myopathic weakness attributable to glucocorticoid 
myopathy. 
 
Central serous retinopathy: a fluid detachment of macula layers from their supporting tissue.  Requires formal ophthalmology examination, 
typically accompanied by optical coherence tomography and/or fluorescein angiography for diagnostic confirmation.  
 
Grade 4 infection: Life-threatening consequences (e.g., septic shock, hypotension, acidosis, necrosis). 
 
Diabetic nephropathy: Macroalbuminuria; i.e., a urinary albumin excretion > 300 mg in a 24-hour collection or a urinary protein: creatinine ratio 
> 300mg/g.  
 
Diabetic neuropathy:  Any of four types of peripheral neuropathy occurring in the setting of diabetes mellitus, namely: 1) a distal sensory 
polyneuropathy; 2) autonomic neuropathy (hypoglycemia unawareness, bladder or bowel problems, erectile dysfunction, and other autonomic 
nervous system issues); 3) diabetic amyotrophy (muscle infarction); or 4) mononeuritis (e.g., foot drop attributed to diabetic neuropathy). 
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Diabetic retinopathy:  Any form of retinopathy associated with diabetes mellitus, including both non-proliferative and proliferative forms of 
diabetic retinopathy as well as diabetic macular edema.  These complications must be confirmed by an ophthalmologist. 
 
Severe skin toxicity: Any of the three following manifestations: 
Grade 4 acneiform lesions - Papules and/or pustules covering any % body suraface area (BSA), which may or may not be associated with symptoms of 
pruritus or tenderness and are associated with extensive superinfection with IV antibiotics indicated or life- threatening consequences 
Grade 3 striae - Covering >30% BSA or associated with ulceration 
Grade 3 ulcers - Combined area of ulcers >2 cm or full-thickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend 
down to fascia 
 
References 
National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 NCI, NIH, DHHS. May 29, 2009 NIH publication # 09-7473. 
Medical Research Council of the United Kingdom. Guide to Examination of the Peripheral Nervous System: Memorandum No 45. Palo Alto, Calif: Pedragon 
House; 1978. 
American Heart Association. Hypertensive Crisis. Accessed 
http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/Hypertensive-Crisis_UCM_301782_Article.jsp#.V0NnSzv2ZaQ. 
5/1/2015. 
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Supplementary Table 1.  List of External Testers 
 
Tester Specialty Institution 
Dr. George Stojan Rheumatology Beth Israel Deaconess Medical Center 
Dr. Kostantinos Tselios Rheumatology University of Toronto 
Dr. Charis Papadopoulou Pediatric Rheum Great Ormond Street Hospital 
Dr. Despina Eleftheriou Pediatric Rheum Great Ormond Street Hospital 
Dr. Lorcan McGarvey Pulmonology Queen’s University, Belfast 
Dr. Julianna Desmarais Rheumatology Oregon Health Sciences University 
Dr. Sheenal Patel Allergy/Immunology University of Texas-Southwestern 
Dr. Zachary Wallace Rheumatology Massachusetts General Hospital 
Dr. Marlies van der Goes Rheumatology University of Utrecht 
Dr. Matthew Cascino Rheumatology University of California-San Francisco 
Dr. Stephen McAdoo Nephrology Hammersmith Hospital 
Dr. Sandra Hermann Rheumatology Charite Hospital 
Dr. Alexa Shipman Dermatology West Midlands Deanery, Birmingham, UK 
Dr. Cory Perugino Rheumatology Massachusetts General Hospital 
Dr. Matthew Tremblay Neurology University of California-San Fran 
Dr. Erin Wilfong Rheumatology University of California-San Francisco Dr. Mark Matsos Rheumatology McMaster University, Canada 
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